1. Genetic landscape of colorectal cancer patients manifesting tumor shrinkage during SARS-Cov-2 infection
- Author
-
Alessandro Ottaiano, Mariachiara Santorsola, Luisa Circelli, Marco Cascella, Nadia Petrillo, Francesco Perri, Marika Casillo, Vincenza Granata, Monica Ianniello, Francesco Izzo, Carmine Picone, Marco Correra, Antonella Petrillo, Roberto Sirica, Gabriella Misso, Paolo Delrio, Guglielmo Nasti, Giovanni Savarese, Michele Caraglia, Ottaiano, A., Santorsola, M., Circelli, L., Cascella, M., Petrillo, N., Perri, F., Casillo, M., Granata, V., Ianniello, M., Izzo, F., Picone, C., Correra, M., Petrillo, A., Sirica, R., Misso, G., Delrio, P., Nasti, G., Savarese, G., and Caraglia, M.
- Subjects
next generation sequencing ,Oncology ,SARS-CoV-2 ,COVID-19 ,colorectal cancer ,genetic - Abstract
We previously described three patients affected by metastatic colorectal cancer (mCRC) who experienced spontaneous tumour shrinkage during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Thereafter, the patients were closely monitored and no systemic treatments were applied. Here, we report follow-up clinical information about these patients as well as genetic characterization of their primary tumours through the TruSigt™Oncology 500 Next Generation Sequencing test targeting 523 cancer-relevant genes. An Illumina NovaSeq 6000 platform was used to perform sequencing. Time-to-progression was 23 and 2 months, respectively, in Patients 2 and 3 while it was not reached in Patient 1. Patients 1 and 2 had the greatest anti-SARS-CoV-2 IgG titres. Assessment of genetic landscapes evidenced common mutation in BARD1 gene (p.Val507Met) in Patients 1 and 2. Although our report is descriptive in its nature, we suggest that complex and unexplored interactions between genetic background and components of the immune response to SARS-CoV-2 infection could be responsible of unexpected rare mCRC shrinkage.
- Published
- 2022
- Full Text
- View/download PDF